Analyzing SAB Biotherapeutics (SABS) & Its Rivals

SAB Biotherapeutics (NASDAQ:SABS) is one of 844 publicly-traded companies in the “Biotechnology” industry, but how does it contrast to its rivals? We will compare SAB Biotherapeutics to related companies based on the strength of its profitability, institutional ownership, analyst recommendations, dividends, risk, earnings and valuation.

Valuation and Earnings

This table compares SAB Biotherapeutics and its rivals revenue, earnings per share and valuation.

	Gross Revenue	Net Income	Price/Earnings Ratio
SAB Biotherapeutics	$1.32 million	$13.27 million	-2.40
SAB Biotherapeutics Competitors	$691.14 million	$10.43 million	-10.01

SAB Biotherapeutics’ rivals have higher revenue, but lower earnings than SAB Biotherapeutics. SAB Biotherapeutics is trading at a higher price-to-earnings ratio than its rivals, indicating that it is currently more expensive than other companies in its industry.

Profitability

This table compares SAB Biotherapeutics and its rivals’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
SAB Biotherapeutics	N/A	-6.74%	-6.06%
SAB Biotherapeutics Competitors	-9,046.59%	-199.78%	-30.61%

Volatility and Risk

SAB Biotherapeutics has a beta of 0.67, meaning that its stock price is 33% less volatile than the S&P 500. Comparatively, SAB Biotherapeutics’ rivals have a beta of 1.14, meaning that their average stock price is 14% more volatile than the S&P 500.

Institutional and Insider Ownership

7.8% of SAB Biotherapeutics shares are owned by institutional investors. Comparatively, 47.9% of shares of all “Biotechnology” companies are owned by institutional investors. 7.4% of SAB Biotherapeutics shares are owned by insiders. Comparatively, 13.0% of shares of all “Biotechnology” companies are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.

Analyst Recommendations

This is a breakdown of current ratings and target prices for SAB Biotherapeutics and its rivals, as provided by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
SAB Biotherapeutics	1	1	9	0	2.73
SAB Biotherapeutics Competitors	9789	15054	45300	1571	2.54

SAB Biotherapeutics currently has a consensus target price of $12.00, indicating a potential upside of 284.62%. As a group, “Biotechnology” companies have a potential upside of 97.61%. Given SAB Biotherapeutics’ stronger consensus rating and higher probable upside, analysts clearly believe SAB Biotherapeutics is more favorable than its rivals.

Summary

SAB Biotherapeutics beats its rivals on 7 of the 12 factors compared.

SAB Biotherapeutics Company Profile

SAB Biotherapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development of human polyclonal immunotherapeutic antibodies to address immune system disorders and infectious diseases. It has applied advanced genetic engineering and antibody science to develop transchromosomic bovine herds that produce fully human antibodies targeted at infectious diseases and immune and autoimmune disorders, including infectious diseases, influenza, CDI, type 1 diabetes, organ transplantation, and oncology, as well as immunology, gastroenterology, and respiratory diseases. The company also uses its DiversitAb immunotherapy platform to produce fully-human polyclonal antibodies without the need for human donors or plasma. In addition, its lead product candidate SAB-142, a human, multi-target anti-thymocyte globulin treatment, currently under Phase 1 trials in delaying the onset or progression of type 1 diabetes. Further, the company develops SAB-176, a multivalent, broadly neutralizing – human polyclonal immunoglobulin therapeutic candidate, currently in Phase 2a development for the treatment or prevention of severe influenza. SAB Biotherapeutics, Inc. was founded in 2014 and is headquartered in Miami Beach, Florida.